natgillin/translations-raw huggingface dataset:
The use of a combination of any one of claims 1 to 6 for the manufacture of a medicament for the treatment or prevention of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage. 
Primjena spoja prema bilo kojem od zahtjeva 1 do 9, ili njegove farmaceutski prihvatljive soli, stereoizomera ili tautomera, naznačena time što služi za proizvodnju lijeka za liječenje ili prevenciju tumora, upalnih bolesti, reperfuzionih povreda, iskemijskih stanja, moždanog udara, bubrežne insuficijencije, kardiovaskularnih bolesti, vaskularnih bolesti različitih od kardiovaskularnih bolesti, dijabetesa, neurodegenerativnih bolesti, retrovirusnih infekcija, oštećenja mrežnice ili starenja kože i oštećenja kože izazvanih UV-zračenjem.
determining a second MACERS for a subject based upon, at least in part, the ratio of ST2 T2 to ST2 T0, in addition to a weighted natural logarithm of NP T2 according to the following formula: Second MACERS=(ST2T2/ST2T0) +aln(NP T2), wherein a is a weighting factor; identifying a subject having a second MACERS that is increased as compared to the first MACERS, and determining that the identified subject's condition is declining; and 
(NP T2) prema slijedećoj formuli: Drugi MACERS = (ST2 T2/ST2 T0) + oln(NP T2), gde je a težinski faktor; uspoređujući drugi MACERS prema prvom MACERS; 1 određivanje da je tretman efikasan kod pacijenta koji ima drugi MACERS koji je umanjen u usporedbi sa prvim MACERS, ili da tretman nije bio efikasan kod pacijenta koji ima drugi MACERS jednak ili uvećan u usporedbi sa prvim MACERS.
a separation unit for separating the carbon obtained by decomposing and the hydrogen obtained by decomposing, the separation unit having separate outlets for carbon and hydrogen, wherein the outlet for hydrogen of the separation unit is connected to a separate inlet pipe for hydrogen leading into the CO2 converter or into a mixing chamber located downstream. 
jedinicu za razdvajanje za razdvajanje ugljika dobivenog razgradnjom i vodika dobivenog razgradnjom, jedinica za razdvajanje ima posebne izlaze za ugljik i vodik, pri čemu je izlaz za vodik povezan sa zasebnom ulaznom cijevi za vodik;
circumferential wall of the enclosing (bell) member 26 
obodna stijenka elementa za obuhvaćanje (zvona) 26
. R5 and R6 represent hydrogen atoms or alkyl or haloalkyl groups, said alkyl and haloalkyl groups containing from 1 to 4 carbon atoms, 
R5 i R6 predstavljaju vodikove atome ili alkil ili haloalkil skupine, te navedene alkil i haloalkil skupine sadrže od 1 do 4 ugljikova atoma, .
A, L1, and L2 are components of the linker; 
A,L'i L* su komponente od poveznice L,
A method of assessing the therapeutic efficacy of a drug targeting human cells, the method comprising: administering a drug candidate to a rodent according to any one of claims 1-3 into which one or more human cells have been transplanted; and 
Postupak procjenjivanja terapijske djelotvornosti lijeka koji cilja na ljudske stanice, naznačen time što se postupak sastoji u: primjeni kandidatnog lijeka na glodavcu u skladu s bilo kojim od patentnih zahtjeva 1-3, u kojeg je presađena jedna ili više ljudskih stanica; i praćenju ljudskih stanica u glodavcu kako bi se odredilo terapijsku djelotvornost kandidatnog lijeka.
A composition comprising (a) a cyclodextrin, (b) a compound of Formula (III) or a pharmaceutically acceptable salt thereof, and (c) a pH adjusting agent. 
Sastav sadržeći (a) ciklodekstrin, (b) spoj Formule (III): HNGOH poi O HR P20180690 T1 ili farmaceutski prihvatljivu sol istog, te (c) agens prilagodbe pH vrijednosti.
The pharmaceutical composition according to claims 8 to 12, wherein the TNFa inhibitor is an anti-TNFa antibody. A kit comprising 
Farmaceutski pripravak u skladu s patentnim zahtjevima 8 do 12, naznačen time, da TNFqa inhibitor je protu-TNFa protutijelo.
A plant according to claim 1 or 2, characterized in that the communicating duct (18) comprises an upper inclined portion, having an upper inlet (21) that opens on the combustion chamber (10) and said lower end portion (18a). 
Postrojenje u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što komunikacijski vod (18) ima gornji nagnuti dio, koji ima gornji ulaz (21), koji se otvara na komori izgaranja (10) i navedeni donji dio (184).
The reaction is conveniently carried out in a suitable solvent, such as an aprotic solvent, e.g. dimethylformamide in the presence of a suitable catalyst, for example a metal hydride. 
Rcakciju sc pogodno provodi u pogodnom otapalu, poput neprotonskog otapala, primjerice dimetilformamida, u prisutnosti pogodnog katalizatora, primjerice metalnog hidrida.
The compound according to claim 8 wherein X1 is O and Y is connected to X1 via an w-amino aminocarbonyl cyclization spacer being part of Y. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time što je X1 O, a Y je povezan s X1 putem w-amino aminokarbonilne ciklizacijske razmaknice koja je dio Y.
Preferably, the invention further comprises purification steps selected from immobilized metal ion affinity chromatography, ion exchange chromatography, hydrophobic interaction chromatography and reverse phase chromatography. 
Najvažnije je to što ovaj izum sadrži korake za pročišćavanje koji su probrani iz afinitetne kromatografije s imobiliziranim metalnim ionima, kromatografije s pomoću izmijene iona, kromatrografije hidrofobnih interakcija te kromatografije obrnute faze.
In one embodiment, the rodent is selected from the group consisting of a mouse and a rat. 
U glodavca iz zahtjeva 7. glodavac je miš, a glodavačke dijelove kimernog MHC II a.
an antigen composition; and an adjuvant composition according to claim 1 . A trisaccharide derivate, wherein the core of the derivate is derived from raffinose, melezitose, or maltotriose and wherein the core is fully substituted with one sulphate ester or phosphate ester group and ten identical fatty acid ester groups; or with two sulphate or phosphate ester groups and nine identical fatty acid ester groups, wherein the fatty acid ester groups are esters of a straight, branched, saturated or unsaturated fatty acid with a chain length of 4 to 20 carbon atoms. 
Postupak dobivanja trisaharidnog derivata u skladu s bilo kojim od patentnih zahtjeva 17-19, naznačen time što se sastoji u koracima: a) osiguravanja trisaharida i njegovog otapanja u otapalu, gdje je trisaharid rafinoza, melezitoza ili maltotrioza; 1 b) esterificiranju svih OH-skupina u trisaharidu, gdje najmanje jedna od OH-skupina u trisaharidu reagira s anionskim sredstvom, gdje se trisaharid esterificira s prosječno jednom sulfatnom ili fosfatnom esterskom skupinom i deset istovjetnih esterskih skupina masnih kiselina po trisaharidu ili s dvije sulfatne ili fosfatne esterske skupine i devet istovjetnih esterskih skupina masnih kiselina po trisaharidu, gdje je masna
(1-7) a C1-C6 alkoxy group. The method according to claim 4, wherein in the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof is selected from 
Heterociklički spoj, naznačen time, da je predstavljen općom formulom (1) ili njegova sol u skladu s patentnim zahtjevom 4, koji je odabran od (4aS,8aR)-1-(4-klorofenil)-3,3-dimetildekahidrokinoksalina,
1N HCl solution (2 mL) was added, followed by the addition of NaOH until pH>7. 
Pripravak prema zahtjevu 1, naznačen time da je dodatno sredstvo protuupalno sredstvo.
j is ranging from zero to 4; y is ranging from zero to 4; G is a divalent linker selected from the group consisting of: a bond, C2-C6-alkynylene, -[CONR25]-; 
je vodik ili (C1-C6)alkil; j je u rasponu od nula do 4; y je u rasponu od nula do 4; G je dvovalentna spojnica odabrana iz skupine koju čine: veza, C2-C6-alkinilen, -[CONR25]-;
A method of growing stone fruit, said method comprising thinning a stone fruit bearing tree according to the method of claim 1, and harvesting the fruit in the second year. 
Postupak sukladno bilo kojem od patentnih zahtjeva 2-14, naznačen time, da taj postupak sadrži ubiranje koštuničavog voća u drugoj godini.
The compound of claim 2, wherein the compound is a Form I hydrobromic acid salt characterized by three or more peaks in a powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta. 
Spoj prema zahtjevu 2, pri čemu spoj je Oblik I soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 17.39, oko 19.45, oko 21.41, oko 23.56 1 oko 27.45 stupnjeva 2-theta.
The liquefied gas treatment method according to claim 1, wherein, in the ballast condition, the LNG stored in the cargo tank (1;11) is supplied as fuel to the main engine and the sub engine through the pump line (110;L23). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se pomoćna linija za slanje LNG (1.24) grana od glavne linija za slanje LNG (L23) na uzvodnoj strani visokotlačne crpke (43).
subjecting the second stream to a second separation stage which comprises a centrifugal separation step, capable of recovering suspended solids from a liquid, to recover a third stream rich in the fermentation agent including soluble non-starch polysaccharides and a fourth stream rich in the aqueous solution; and formulating the recovered fermentation agent as a protein source in a feed material for use in an animal feed composition. 
(iv) podvrgavanje druge struje drugoj fazi odvajanja koja obuhvaća korak centrifugalnog odvajanja, sposobne za ponovno dobivanje suspendirane krute tvari 1z tekućine, da se dobije treća struja bogata s fermentacijskim sredstvom koje obuhvaća topive ne-škrobne polisaharide i četvrta struja bogata s vodenom otopinom; te formuliranje obnovljenog fermentacijskog sredstva kao izvora proteina kao krmiva za uporabu u pripravku hrane za životinje.
The invention also relates to nucleic acids and genetic products which are expressed in association with a tumor cell. 
(54) Naziv izuma: GENSKI PROIZVODI KOJI SU DIFERENCIJALNO IZRAŽENI U TUMORIMA I NJIHOVO
Process according to one of claims 1 to 10, wherein the addition of the at least one water-soluble acid of step b) and the contacting of said aqueous calcium carbonate containing mineral slurry of step a) with said acid of step b) and with said CO2 generated in situ and/or supplied externally of step d) take place in a stirred reactor under stirring conditions such as to develop an essentially laminar flow. 
Postupak prema jednom od zahtjeva 1 do 9, naznačen time da se dodavanje barem jedne kiseline koja se otapa u vodi iz koraka b) i dovođenje u kontakt navedene vodene suspenzije koja sadrži kalcijev karbonat koji sadrži mineral iz koraka a) s navedenom kiselinom iz koraka b) i s navedenim CO, nastalim na licu mjesta i/ili koji se dobavlja iz vanjskog izvora iz koraka c) odvija u miješanom reaktoru uz miješanje tako da nastaje u biti laminarno strujanje.
Mean plasma pharmacokinetic metrics data 
Ovisnost prosjećne koncentracije plazma
is a C10-C22 alkynyl group, said lipid compound being derived from lipids containing 1-6 triple bonds; and 
Ri je C1o-C2 alkinil, te se navedeni lipidni spoj dobije od lipida koji sadrže 1-6 trostrukih veza;
comprising the asymmetric hydrogenation of a compound of formula (IV) 
dodatak otopine koja sadrži sredstvo za spajanje u otapalu.
a main branch that connects the first movable contact with the first changeover contact; 
glavna grana (8) koja izravno povezuje prvi pokretni kontakt (6) s prvim preklopnim kontaktom (2.1);
The antibody or fragment thereof according to claim 14 or 15, further comprising at least one of the following sequences: 
Antitijelo ili njegov fragment prema zahtjevu 9, koji dalje sadrži najmanje jednu od slijedećih sekvenci:
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 100, 80, and 101 in which 1 or 2 amino acids are substituted, wherein said peptide induces a cytotoxic T cell specific to a cell expressing ETC2. 
Peptid od manje od 15 aminokiselina koja može inducirati citotoksične T-stanice, gdje navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34, te 358, u kojem su 1 ili 2 aminokiseline zamijenjene, izbačene ili dodane, naznačen time što navedeni peptid inducira citotoksične T-limfocite specifične za stanicu koja eksprimira CDH3.
The method of any of paragraphs 1-15, wherein step (a) is repeated after about 1 minutes to 20 minutes after the first application of the formulation. 
Postupak prema bilo kojem od zahtjeva 1-14, naznačen time da je korak (a) ponovljen 1 minutu do 20 minuta nakon prvog nanošenja formulacije.
A method of improving the bioavailability of a renin inhibitor, which method comprises co-administering, to a mammal in need such treatment, a combination of a renin inhibitor and an efflux protein inhibitor, wherein the efflux protein inhibitor is PSC833 and the renin inhibitor is a σ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative represented by the formula 
. Uporaba inhibitora istjecanja proteina u poboljšanju bioraspoloživosti inhibitora renina, naznačena time, da inhibitor renina je derivat amida 8-amino-y-hidroksi-Q-aril-alkanoične kiseline ili njegova farmaceutski prihvatljiva sol, te pri čemu inhibitor istjecanja proteina je inhibitor MDRI.
separating said precipitate, wherein the sequence in which steps (i) and (ii) are performed can be interchanged and wherein the excess of zinc is removed before formation of said precipitation. 
HR P20170171 T1 pri čemu se sekvenca u kojoj se provode koraci (i) i (ii) može zamijeniti i pri čemu se suvišak cinka uklanja prije formiranja navedenog taloga.
The method of claim 2, wherein said desired harmonic level is generated by selecting a clearance between the guide collet and the bar stock in a range of 0.0002 to 0.005 inches. 
Postupak sukladno zahtjevu 1, pri čemu, je željena harmonična razina dobivena odabirom razmaka između vodiča metalnog optoka i materijala u opsegu od 0.0051 mm do 0.127 mm.
which contains the pharmacologically active agent according to general formula (I) in a dose of from 150 µg to 800 µg; and wherein the pharmacokinetic parameter tmax is within the range of from 0.5 to 16 h, for use in the treatment of nociceptive pain. 
- koji sadrži farmakološki aktivno sredstvo u dozi od 10 ug do 190 ug, izraženo kao doza ekvivalentne težine na osnovi slobodne baze; i - pri čemu je farmakokinetički parametar tax, izražen kao srednja vrijednost, u rasponu od 0,5 do 16 h; naznačen time da je za upotrebu za liječenje kronične neuropatske boli, pri čemu se farmaceutski oblik doziranja primjenjuje oralno jednom dnevno.
This approach is limited to unsaturated fatty acids where the alkene group in the fatty acid makes an oxidative crosslinking possible. 
Taj pristup je ograničen na nezasićene masne kiseline u kojima alkenska skupina u masnoj kiselini omogućuje oksidativno umreživanje.
An antigen binding protein of any one of claims 1-5, wherein said antigen binding protein has at least one property selected from the group consisting of: reducing human IL-23 activity in a STAT-luciferase assay; reducing production of a proinflammatory cytokine; 
Protein koji veže antigen iz bilo kojeg od patentnih zahtjeva 1-5, pri čemu navedeni protein koji veže antigen ima najmanje jedno svojstvo odabrano iz grupe koja se sastoji od: a) < smanjivanja aktivnosti ljudskog IL-23 u određivanju metodom STAT-luciferaze; b) smanjivanje stvaranja proupalnih citokina;
Frozen or deep-frozen Viennese pastries, croissants, or chocolate rolls, having an upper and a lower surface, characterised in that at least said lower surface comprises the shape of multiple arches which are tandemly arranged. 
Smrznute ili duboko smrznute slastice od tijesta, kroasani ili čokoladne rolice, koje imaju gornju i donju površinu, naznačene time, da barem navedena donja površina ima oblik višestrukih lukova koji su raspoređeni u paru.
to 10 % by weight of lubricant. 
E) 0,1 do 10 % masenog udjela maziva.
Pirfenidone for use in treating a patient according to aspect 1, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 1600 mg/day for a time period. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 1, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 1600 mg/dan u tijeku vremenskog perioda.
The method of claim 7, wherein the disease, disorder and/or condition is hemochromatosis. 
obuhvaća modificirani šećer, opcionalno gdje je modificirani šećer biciklični šećer; i/ili
Elution was carried out in gradient mode using the combination of elution solution A and elution solution B as following detailed: 
S elucijom se nastavilo u gradijentu koji koristi kombinaciju elucijskih otopina A i B na način na koji je to navedeno ispod:
A method of forming and cutting the lid (10) of claim 2 or claim 3 for a beverage cup (31) from an unformed thermoplastic sheet, a material that becomes pliable above a specific temperature and retains a molded shape upon cooling, said lid (10) including the features of claim 3, said method comprising: 
Postupak za oblikovanje i rezanje poklopca (10) prema zahtjevu 2 ili zahtjevu 3 za šalicu za piće (31) iz neoblikovane termoplastične ploče, materijal koji postaje savitljiv iznad specifične temperature i zadržava
Cell density was measured using a haemocytometer and viability was calculated using Trypan Blue solution before being further diluted in Growth Medium and seeded at a density of 1×104 cells per well (in 100 ul) into clear bottomed 96 well plates (Packard, No. 
Gustoća stanica izmjeri se hemocitometrom i vijabilnost izračuna koristeći otopinu Tripan-plavo prije daljnjeg razrijeđivanja u hranjivom mediju i nasađivanja u mikrotitarske pločice sa prozirnim dnom (Packard, No.
A pharmaceutical composition comprising a compound of Formula (I) according to claim 1 and a pharmaceutically acceptable diluent and/or carrier. 
Farmaceutski pripravak koji sadrži spoj formule (1) prema patentnim zahtjevima 1-7 i farmaceutski prihvatljiv razrjeđivač i/ili nosač.
The use of a compound of formula (II): wherein: 
Upotreba spoja formule (II):
Demultiplexer circuit 12a, 12b performs this operation by means of sequential logic synchronous with the clock signal by which data is transmitted over serial transmission channel 10a, 10b. 
Demultipleksni komunikacijski krug 12a, 12b izvodi ovu operaciju pomoću sekvencijalne logike sinkrono sa satnim signalom koji se podaci prenose preko serijskog prijenosnog kanala 10a, 10b.
In one embodiment, the invention provides a composition comprising phentermine and a selective 5HT-2C receptor agonist wherein said selective 5HT-2C receptor agonist is (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. 
. Pripravak u skladu sa zahtjevom 1, naznačen time, da navedeni selektivni agonist 5HT-2C receptora je (R)-8- kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin ili njegova farmaceutski prihvatljiva sol, solvat i hidrat.
The tumour is selected, in particular, from the group of diseases of the squamous epithelium, bladder, stomach, kidneys, head, neck, oesophagus, cervix, thyroid, intestine, liver, brain, prostate, urogenital tract, lymphatic system, larynx, lung, skin, blood and immune system, and/or the cancer is selected from the group of monocytic leukaemia, lung adeno-carcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma, bowel carcinoma, breast carcinoma, acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leukaemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma. The present invention additionally relates to a process for the preparation of a medicament, preferably for use in the treatment of cancer and/or tumours, preferably the types of cancer or tumour mentioned above, comprising: 
Spoj i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer, stereoizomer za uporabu prema jednom od patentnih zahtjeva 5 do 7 naznačen time što je tumor odabran iz skupine bolesti skvamoznog epitela, mjehura, želuca, bubrega, glave, vrata, jednjaka, grlića maternice, štitnjače, crijeva, kosti, jetre, mozga, prostate, urogenitalnog trakta, limfnog sustava, grkljana, pluća, kože, krvi i imunološkog sustava, i/ili rak je odabran iz skupine koju čine monocitna leukemija, adenokarcinom pluća, karcinom pluća malih stanica, rak gušterače, glioblastom, karcinom crijeva, karcinom dojke, akutna mijeloična leukemija, kronična mijeloična leukemija, akutna limfatična leukemija, kronična limfatična leukemija, Hodgkinov limfom i ne-Hodgkinov limfom.
A method of connecting to a preferred network at a communication device, the method comprising: providing notification to a central server (108) relating to a change in the current location for the communication device; receiving a subscriber network identifier provisioned according to the method of any of claims 1 to 15, if the central server has determined that the communication device is not connected to the preferred network; and 
HR P20141037 T1 osiguravanje obavještavanja centralnom serveru (108) koje se odnosi na promjenu trenutne lokacije komunikacionog uređaja; prijem pretplatničke mrežne identifikacije koja je osigurana postupkom prema bilo kom od zahtjeva 1 do 15, ukoliko je centralni server odredio da komunikacioni uređaj nije povezan na najpoželjniju mrežu; i isključivanje sa trenutne mrežne konekcije i ponovno povezivanje na poželjnu mrežu koristeći primljenu pretplatničku mrežnu identifikaciju.
For example, a release button or the like could be depressed or actuated in order to switch from the discharge state into the non-discharge state without the necessity to rotate or twist any element. 
Na primjer, za prebacivanje iz stanja za pražnjenje u stanje ne-pražnjenja može se rasteretiti ili pokrenuti dugmc za rasterećenje ili slično bez nužnog okretanja ili uvijanja bilo kojeg clementa.
Rb2 and Rb6 are independently selected from hydrogen, methyl, and fluoride; 
Rb2i Rby su neovisno odabrani od sljedećih: vodik, metil 1 fluor;
dermatological diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
(v) dermatoloških bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
The aforementioned considerations have led to the design of a new supporting device for electric or electronic components characterised by clean aesthetics and by the possibility of being camouflaged and integrated into the continuous surface of the wall thanks to the fact that the front cover is perfectly flush with the wall. 
Prije spomenuta razmatranja su dovela do izvedbe novog uređaja za ugradnju električnih i elektroničkih komponenti, koji uređaj je karakterističan po čistoj estetici i po mogućnosti da bude kamufliran i ugrađen u neprekinutu površinu zida zahvaljujući činjenici što je prednji poklopac savršeno izravnan sa zidom.
said first constituent is a glycosaminoglycan, a hydrolysed glycosaminoglycan, a glycosamine, chemically modified or not or a blend of different glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines, chemically modified or not; 
spomenuti prvi sastojak je glikozaminoglikan, hidrolizirani glikozaminoglikan, glikozamin, kemijski modificirani ili ne ili mješavina različitih glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina, kemijski modificiranih ili ne;
is attached to the ring N of the pyrrolidine, and m is 0. 
S C R3 je vezan na N u prstenu pirolidina, a m je nula.
in an amount of 30 mg/kg per week; and/or 
(a) u količini od 30 mg/kg tjedno; i/ili
(Xlla) reacting an intermediate of formula (XXIV) with HR9 in the presence of a suitable base and a suitable solvent, With R1, R2, R9 and n as defined in claim 1; 
(XIIa) reakcija intermedijera formule (XXIV) s HR9 u prisutnosti prikladne baze i prikladnog otapala, [image] s R1, R2, R9 i n kako su definirani u zahtjevu 1;